AGC Biologics has appointed Luca Alberici to take on the role of General Manager/Site Head at the company’s Milan, Italy site. Mr. Alberici will transition from his role as Chief Business Officer of MolMed. He will initiate integration efforts resulting from the July 2020 acquisition of MolMed, a biotechnology company focused on research, development, production and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases.

Mr. Alberici will provide leadership and site management to ensure the continued execution of cell and gene therapy contract development and manufacturing services from the Milan site. He will support the continuous growth of the site while working closely with colleagues in Seattle, Heidelberg and China to ensure the business leverages and integrates AGC Biologics combined global capabilities.

“We are very happy to be able to appoint Mr. Alberici to General Manager/Site Head at the Milan, Italy site. He will ensure continuity in leadership at the Milan Site and he will be instrumental in further developing the capacity and capabilities of the site,” said Kasper Moller, AGC Biologics Chief Technology Officer. “Mr. Alberici’s track record within the Cell and Gene therapy field and his demonstrated leadership are great assets to our team and he will assure continued high performance of the Milan Site and development of the Cell and Gene Therapy area.”